title: HCV and the hepatic lipid pathway as a potential treatment target.
abstract: Atherosclerosis has been described as a liver disease of the heart [1]. The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus-host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3]. One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: • update the hepatologist on lipid metabolism • review the evidence that HCV exploits hepatic lipid pathways to its advantage • discuss approaches to targeting host lipid pathways as adjunctive therapy.
authors: Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. m.bassendine@ncl.ac.uk
authors: Margaret F
authors: MF
authors: Bassendine
authors: David A
authors: DA
authors: Sheridan
authors: Daniel J
authors: DJ
authors: Felmlee
authors: Simon H
authors: SH
authors: Bridge
authors: Geoffrey L
authors: GL
authors: Toms
authors: R Dermot G
authors: RD
authors: Neely
mesh_terms: D001054:Apolipoproteins A / Q000378:metabolism; D001055:Apolipoproteins B / Q000378:metabolism; D001057:Apolipoproteins E / Q000378:metabolism; D002914:Chylomicrons / Q000378:metabolism; D016174:Hepacivirus / Q000378:metabolism / Q000472:pathogenicity; D006526:Hepatitis C / Q000378:metabolism* / Q000628:therapy* / Q000821:virology; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D050356:Lipid Metabolism / Q000187:drug effects; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D053858:Metabolic Networks and Pathways; D008954:Models, Biological
chemical_list: D001054:Apolipoproteins A; D001055:Apolipoproteins B; D001057:Apolipoproteins E; D002914:Chylomicrons; D000960:Hypolipidemic Agents; D008079:Lipoproteins, VLDL